A Review of Anti-C Reactive Protein Antibodies in Systemic Lupus Erythematosus

1. Figueredo MA, Rodriguez A, Ruiz-Yagüe M, et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol. 2006;33:1980-1986.Search in Google Scholar

2. Li QY, Li HY, Fu G, Yu F, Wu Y, Zhao MH. Autoantibodies against C-reactive protein influence complement activation and clinical course in lupus nephritis. J Am Soc Nephrol. 2017;28:3044-3054.10.1681/ASN.2016070735Search in Google Scholar

3. Jakuszko K, Krajewska M, Kościelska-Kasprzak K, et al. Antibodies against monomeric C-reactive protein–a promising biomarker of lupus nephritis? Clin Biochem. 2017;50:756-762.Search in Google Scholar

4. Sjowall C, Eriksson P, Almer S, Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren’s syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun. 2002;19:155-160.10.1006/jaut.2002.0608Search in Google Scholar

5. Dumestre-Pérard C, Clavarino G, Colliard S, Cesbron JY, Thielens NM. Antibodies targeting circulating protective molecules in lupus nephritis: interest as serological biomarkers. Autoimmun Rev. 2018;17:890-899.10.1016/j.autrev.2018.03.013Search in Google Scholar

6. Doria A, Gatto M. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus. 2012;21:1492-1496.10.1177/0961203312462267Search in Google Scholar

7. Pesickova SS, Rysava R, Lenicek M, et al. Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. Arthritis Res Ther. 2015;17:1-7.10.1186/s13075-015-0879-8Search in Google Scholar

8. O’Neill SG, Giles I, Lambrianides A, et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with lupus erythematosus. Arthritis Rheum. 2010;62:845-854.10.1002/art.27286Search in Google Scholar

9. Robey FA, Jones KD, Tanaka T, Liu TY. Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J Biol Chem. 1984;259:7311-7316.10.1016/S0021-9258(17)39873-3Search in Google Scholar

10. Bell SA, Faust H, Schmid A, Meurer M. Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol. 1998;113:327.10.1046/j.1365-2249.1998.00655.x19050699737658Search in Google Scholar

11. Sjöwall C, Olin AI, Skogh T, et al. C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. Autoimmunity. 2013;46:205-214.10.3109/08916934.2013.76499223331132Search in Google Scholar

12. Son CN, Lee TH, Bang JH, et al. The relationship between anti-C-reactive protein and disease activity in patients with systemic lupus erythematosus. Korean J Intern Med. 2018;33:823.10.3904/kjim.2016.065603040328352058Search in Google Scholar

13. Jung JY, Koh BR, Kim HA, Jeon JY, Suh CH. Autoantibodies to C-reactive protein in incomplete lupus and systemic lupus erythematosus. J Investig Med. 2014;62:890-893.10.1097/JIM.000000000000009424896736Search in Google Scholar

14. Kraszewska-Głomba B, Myszka M, Krajewska M, Szenborn L. High Prevalence of Autoantibodies Against Monomeric C Reactive Protein (CRP) in Children with PFAPA Syndrome. J Med Biochem. 2018;37:507-509.10.1515/jomb-2017-0066629847230584411Search in Google Scholar

15. Minatani M, Aotsuka S, Satoh T. Autoantibodies against C-reactive protein (CRP) in sera of patients with systemic rheumatic diseases. Mod Rheumatol. 2001;11:127-131.10.3109/s10165017002324383688Search in Google Scholar

16. Sjöwall C, Bengtsson AA, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2004;6:R87-94.10.1186/ar103240042615059271Search in Google Scholar

17. Rosenau BJ, Schur PH. Antibodies to C reactive protein. Ann Rheum Dis. 2006;65:674-676.10.1136/ard.2005.037895179815416176996Search in Google Scholar

18. Mathsson L, Ahlin E, Sjöwall C, Skogh T, Rönnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren’s syndrome A antibodies. Clin Exp Immunol. 2007;147:513-520.10.1111/j.1365-2249.2006.03313.x181049217302901Search in Google Scholar

19. Shoenfeld Y, Szyper-Kravitz M, Witte T, et al. Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci. 2007;1108:227-239.10.1196/annals.1422.02517899624Search in Google Scholar

20. Kessel A, Rosner I, Halasz K, et al. Antibody clustering helps refine lupus prognosis. Semin Arthritis Rheum. 2009;39:66-70.10.1016/j.semarthrit.2008.03.00318538829Search in Google Scholar

21. Janko C, Franz S, Munoz LE, et al. CRP/anti-CRP antibodies assembly on the surfaces of cell remnants switches their phagocytic clearance toward inflammation. Front Immunol. 2011;2:70.10.3389/fimmu.2011.00070334199522566859Search in Google Scholar

22. Pradhan V, Rajadhyaksha A, Yadav K, et al. Anti-C reactive protein antibodies in Indian patients with systemic lupus erythematosus. Indian J Nephrol. 2013;23:434.10.4103/0971-4065.120341384151224339522Search in Google Scholar

23. Tan Y, Yu F, Yang H, Chen M, Fang Q, Zhao MH. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum Immunol. 2008;69:840-844.10.1016/j.humimm.2008.09.00618852001Search in Google Scholar

24. Schäfer VS, Weiß K, Krause A, Schmidt WA. Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity. Clin Rheumatol. 2018;37:1835-1844.10.1007/s10067-018-4093-329656375Search in Google Scholar

25. Hou C, Jin O, Zhang X. Clinical characteristics and risk factors of infections in patients with systemic lupus erythematosus. Clin Rheumatol. 2018;37:2699-2705.10.1007/s10067-018-4198-829987426Search in Google Scholar

26. El-Serougy E, Zayed HS, Ibrahim NM, Maged LA. Procalcitonin and C-reactive protein as markers of infection in systemic lupus erythematosus: the controversy continues. Lupus. 2019;28:1329-1336.10.1177/096120331877710129779437Search in Google Scholar

27. Atik N, Putri Pratiwi S, Hamijoyo L. Correlation between C-reactive Protein with Malondialdehyde in Systemic Lupus Erythematosus Patients. Int J Rheumatol. 2020;2020:8078412.10.1155/2020/8078412735017332695177Search in Google Scholar

28. Shaaban A, Helmy M, Barakat M, Elneily D, Ahmed O. Serum resistin, insulin resistance and carotid intima-media thickness as an indication of subclinical atherosclerosis in systemic lupus erythematosus patients. Egypt Rheumatol. 2020. [Epub ahead of print] https://doi.org/10.1016/j.ejr.2020.09.001.10.1016/j.ejr.2020.09.001Search in Google Scholar

29. Gao D, Shao J, Jin W, Xia X, Qu Y. Correlations of serum cystatin C and hs-CRP with vascular endothelial cell injury in patients with systemic lupus erythematosus. Panminerva Med. 2018;60:151-155.10.23736/S0031-0808.18.03466-329792017Search in Google Scholar

30. Umare V, Nadkarni A, Nadkar M, et al. Do high sensitivity C-reactive protein and serum interleukin-6 levels correlate with disease activity in systemic lupus erythematosuspatients? J Postgrad Med. 2017;63:92-95.Search in Google Scholar

31. Enocsson H, Gullstrand B, Eloranta ML, et al. C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. Front Immunol. 2021;11:3730.10.3389/fimmu.2020.622326787631233584722Search in Google Scholar

32. Atisha-Fregoso Y, Lima G, Carrillo-Maravilla E, et al. C-reactive protein (CRP) polymorphisms and haplotypes are associated with SLE susceptibility and activity but not with serum CRP levels in Mexican population. Clin Rheumatol. 2018;37:1817-1824.10.1007/s10067-018-4059-529556849Search in Google Scholar

33. El-Banna HS, El Khouly RM, Gado SE. Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity. Clin Rheumatol. 2020;39:1627-1632.10.1007/s10067-019-04899-231907692Search in Google Scholar

34. Qi S, Chen Q, Xu D, Xie N, Dai Y. Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis. Lupus. 2018;27:1582-1590.10.1177/096120331877364329720035Search in Google Scholar

35. Meyer O. Anti-CRP antibodies in systemic lupus erythematosus. Joint Bone Spine. 2010;77:384-389.10.1016/j.jbspin.2010.04.01020627790Search in Google Scholar

36. Sjöwall C, Zickert A, Skogh T, Wetterö J, Gunnarsson I. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther. 2009;11:1-9.10.1186/ar2880300349720003354Search in Google Scholar

37. Yang XW, Tan Y, Yu F, Zhao MH. Interference of antimodified C-reactive protein autoantibodies from lupus nephritis in the biofunctions of modified C-reactive protein. Hum Immunol. 2012;73:156-163.10.1016/j.humimm.2011.12.00722192784Search in Google Scholar

38. Ahn SS, Yoo J, Jung SM, Song JJ, Park YB, Lee SW. Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis. BMC Nephrol. 2020;21:1-9.10.1186/s12882-020-01915-5734164332635898Search in Google Scholar

39. Soliman WM, Sherif NM, Ghanima IM, El-Badawy MA. Neutrophil to lymphocyte and platelet to lymphocyte ratios in systemic lupus erythematosus: Relation with disease activity and lupus nephritis. Reumatol Clin. 2020;16:255-261.10.1016/j.reuma.2018.07.00830166230Search in Google Scholar